Acuta Capital Partners, LLC
Acuta Capital Partners, LLC reported 35 holdings worth US$132M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Acuta Capital Partners, LLC reported 35 holdings worth US$132M as of Sep 30, 2026. Largest: Praxis Precision Medicines, Inc., Whitehawk Therapeutics, Inc. and Tango Therapeutics, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 35
- Value as reported
- US$132M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Praxis Precision Medicines, Inc. | 84,193 | US$24.5M | 18.6% |
| Whitehawk Therapeutics, Inc. | 4.69M | US$17.6M | 13.4% |
| Tango Therapeutics, Inc. | 410K | US$10.2M | 7.8% |
| 4D Molecular Therapeutics, Inc. | 535K | US$7.66M | 5.8% |
| argenx SE | 5,558 | US$5.33M | 4.0% |
| ArriVent BioPharma, Inc. | 171K | US$5.17M | 3.9% |
| Surrozen, Inc. | 153K | US$4.91M | 3.7% |
| Vogenx Inc | 213K | US$4.86M | 3.7% |
| Bright Minds Biosciences Inc. | 93,152 | US$4.64M | 3.5% |
| Ocular Therapeutix, Inc. | 575K | US$4.41M | 3.3% |
| Silence Therapeutics PLC | 394K | US$4.3M | 3.3% |
| Taysha Gene Therapies, Inc. | 692K | US$3.37M | 2.6% |
| Avalyn Pharma Inc. | 115K | US$3.27M | 2.5% |
| Avalo Therapeutics, Inc. | 186K | US$2.86M | 2.2% |
| Opus Genetics, Inc. | 514K | US$2.49M | 1.9% |
| Minerva Neurosciences, Inc | 730K | US$2.44M | 1.9% |
| LB Pharmaceuticals Inc | 52,718 | US$2.02M | 1.5% |
| Artiva Biotherapeutics, Inc. | 260K | US$1.85M | 1.4% |
| Amylyx Pharmaceuticals, Inc. | 62,956 | US$1.83M | 1.4% |
| Revolution Medicines, Inc. | 8,237 | US$1.69M | 1.3% |
| Roivant Sciences Ltd. | 41,535 | US$1.52M | 1.2% |
| Design Therapeutics, Inc. | 115K | US$1.45M | 1.1% |
| United Therapeutics Corporation | 2,240 | US$1.21M | 0.92% |
| Contineum Therapeutics, Inc. | 89,826 | US$1.21M | 0.92% |
| ORIC Pharmaceuticals, Inc. | 87,918 | US$1.18M | 0.90% |
| Erasca, Inc. | 67,541 | US$990K | 0.75% |
| AN2 Therapeutics, Inc. | 142K | US$756K | 0.57% |
| Adial Pharmaceuticals, Inc | 130K | US$521K | 0.40% |
| Sutro Biopharma, Inc. | 25,290 | US$407K | 0.31% |
| Equillium, Inc. | 183K | US$297K | 0.23% |
| Compass Therapeutics, Inc. | 251K | US$261K | 0.20% |
| Stoke Therapeutics, Inc. | 5,771 | US$150K | 0.11% |
Source
Download original · View original at SEC
Related